Pharma BD Deal Intelligence
King Pharmaceuticals' $3.4B all-stock buy of Jones Pharma gave it a durable thyroid franchise—Levoxyl still drove ~4.7% of King's revenue in 2007—but the roll-up strategy it typified collapsed under a Medicaid rebate scandal and $124.1M settlement, with King itself sold to Pfizer in 2011 for just $3.6B.
King expects the transaction to be accretive to earnings immediately upon closing... and will add approximately 3% to 4% to projected earnings per share for…
All-stock deal valued at announcement around $3.4B (1.5 King shares per Jones share); ~half of Jones revenue came from thyroid franchise (Levoxyl, Tapazole,…
Most significant 2000 purchases were Levoxyl, Thrombin and Cytomel; thyroid franchise funded by Altace cash flow and became core to King's branded specialty…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
King Pharmaceuticals announced an all-stock acquisition of Jones Pharma valued at ~$3.4B at announcement (recorded as ~$2.4B pooling at close). Each Jones share exchanged for 1.5 King shares. Brought thyroid franchise and an experienced specialty sales force. Closed Aug 31, 2000.
Assessment window: 5yr post-close.
Hypothyroidism is a chronic endocrine disorder in which the thyroid gland fails to produce sufficient thyroid hormone, requiring lifelong daily replacement; hyperthyroidism (Graves' disease being the most common cause) is the opposite condition treated with antithyroid drugs. Both are common, predominantly female-affecting conditions managed by primary care and endocrinologists.
At the time of the 2000 transaction, the levothyroxine market was dominated by Knoll Pharmaceutical's Synthroid (later acquired by Abbott), with Jones Pharma's Levoxyl and Forest Laboratories' Levothroid as the principal branded competitors, alongside Mylan and other generic levothyroxine sodium suppliers. Cytomel (liothyronine, T3) was effectively the only branded T3 product, and Tapazole (methimazole) was the dominant antithyroid agent for Graves' disease, competing with propylthiouracil generics. Per FundingUniverse and PharmaLetter coverage, the Jones franchise gave King Pharmaceuticals a stable, recurring-script endocrinology platform plus ~100 specialty reps calling on endocrinologists — a complement to King's hospital/critical-care brands like Thrombin-JMI and Brevital. The deal also added Jones's Florida-based specialty sales infrastructure, accelerating King's transition from a manufacturing/contract player to a branded specialty pharma. Investors initially marked both stocks down on integration concerns (FundingUniverse), but shareholders approved in September 2000 and the thyroid franchise became one of King's most durable revenue streams through the Pfizer acquisition in 2010. Sources: https://www.thepharmaletter.com/king-pharmaceuticals-merging-with-jones-pharma-in-3-4-billion-deal and https://www.fundinguniverse.com/company-histories/king-pharmaceuticals-inc-history/
| Deal | Year | Value | Outcome |
|---|---|---|---|
| King Pharmaceuticals Inc. / Jones Pharma Incorporated (this deal) | 2000 | $3.4B | 54 |
| King Pharmaceuticals Inc. / Bristol-Myers Squibb (Corgard/Corzide/Delestrogen/Florinef rights) | 2001 | $285M | 51 |
| King Pharmaceuticals Inc. / Aventis Pharmaceuticals (Intal/Tilade/Synercid rights) | 2002 | $275M | 26 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Novo Holdings A/S / Catalent (manufacturing sites) | 2024 | $11.0B | 81 |
← Browse all deals · How we score deals
More: 2000 deals · King Pharmaceuticals Inc. deals · Metabolic deals